Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States. The company was founded in 1993 and is headquartered in Montreal, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-514-3367800
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$51.45 million
Profitability
Miscellaneous
Employees32
Next Earnings Date7/4/2019 (Estimated)
OptionableNot Optionable
Theratechnologies (TSE:TH) Frequently Asked Questions
What is Theratechnologies' stock symbol?
Theratechnologies trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TH."
When is Theratechnologies' next earnings date?
What price target have analysts set for TH?
3 Wall Street analysts have issued 12 month target prices for Theratechnologies' stock. Their forecasts range from C$10.00 to C$14.50. On average, they expect Theratechnologies' share price to reach C$11.92 in the next twelve months. This suggests a possible upside of 71.0% from the stock's current price. View Analyst Price Targets for Theratechnologies.
What is the consensus analysts' recommendation for Theratechnologies?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theratechnologies.
Has Theratechnologies been receiving favorable news coverage?
Media stories about TH stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Theratechnologies earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the company's share price in the next few days.
Who are some of Theratechnologies' key competitors?
Some companies that are related to Theratechnologies include Genus (GNS), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV), Mesoblast (MSB), Resverlogix (RVX), Polynovo (PNV), Emerald Health Therapeutics (EMH), Starpharma (SPL), Biotest (BIO), Oxford BioMedica (OXB), Neptune Wellness Solutions (NEPT), Senesco Technologies (ELOX), Enochian Biosciences (ENOB), Kodiak Sciences (KOD) and Horizon Discovery Group (HZD).
What other stocks do shareholders of Theratechnologies own?
Who are Theratechnologies' key executives?
Theratechnologies' management team includes the folowing people:
- Mr. Luc Tanguay, Pres, CEO & Non-Independent Director (Age 61)
- Mr. Philippe Dubuc MBA, Sr. VP & CFO (Age 52)
- Mr. Jocelyn Lafond, VP of Legal Affairs & Corp. Sec. (Age 51)
- Mr. Christian Marsolais, Sr. VP & Chief Medical Officer (Age 56)
- Mr. Denis Boucher B.A., L.L.B., VP of Communications & Corp. Affairs (Age 53)
Who are Theratechnologies' major shareholders?
Theratechnologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include Mesirow Financial Investment Management Inc. (0.05%) and Virtu Financial LLC (0.01%). Company insiders that own Theratechnologies stock include Christian Marsolais, Denis Boucher, Jean-Denis Talon, Luc Tanguay, Lyne Fortin, Marie-Noël Colussi and Philippe Dubuc. View Institutional Ownership Trends for Theratechnologies.
Which institutional investors are buying Theratechnologies stock?
TH stock was bought by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc. and Virtu Financial LLC. Company insiders that have bought Theratechnologies stock in the last two years include Christian Marsolais, Denis Boucher, Jean-Denis Talon, Luc Tanguay and Philippe Dubuc. View Insider Buying and Selling for Theratechnologies.
How do I buy shares of Theratechnologies?
Shares of TH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Theratechnologies' stock price today?
One share of TH stock can currently be purchased for approximately C$6.97.
How big of a company is Theratechnologies?
Theratechnologies has a market capitalization of C$536.01 million and generates C$51.45 million in revenue each year. Theratechnologies employs 32 workers across the globe.
What is Theratechnologies' official website?
How can I contact Theratechnologies?
Theratechnologies' mailing address is 2015 Peel St 5th Floor, MONTREAL, QC H3A 1T8, Canada. The company can be reached via phone at +1-514-3367800.
MarketBeat Community Rating for Theratechnologies (TSE TH)
MarketBeat's community ratings are surveys of what our community members think about Theratechnologies and other stocks. Vote "Outperform" if you believe TH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TH will underperform the S&P 500 over the long term. You may vote once every thirty days.
